Setting: Bronx, NY.
INTRODUCTION
To provide broadly effective HIV prevention for women, prevention approaches that protect against both vaginal and rectal HIV acquisition are required. Oral preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) seems to meet this need, as it reduces the risk of both vaginal and rectal HIV acquisition, [1] [2] [3] although daily adherence may be necessary to achieve vaginal protection. 4, 5 Although the evidence is inconsistent, topical PrEP with tenofovir (TFV) 1% gel seems to reduce the risk of vaginal acquisition, especially after adjusting for poor adherence in post hoc analyses. [6] [7] [8] Evidence is lacking, however, regarding whether vaginal PrEP with TFV reduces the risk of rectal HIV acquisition. Given the highly variable rates of heterosexual anal intercourse reported among women worldwide, 9,10 much of which is unprotected, [11] [12] [13] [14] it is critical to understand the crosscompartment distribution of topical vaginal and rectal TFV.
Nonhuman primate studies of TFV gel applied vaginally and rectally have shown evidence of cross-compartment distribution of TFV between the vagina and rectum, in each case down a 1-2 log 10 gradient. 15 The concentrations achieved through cross-compartment distribution were similar to concentrations shown to provide protection to nonhuman primates challenged with SHIV vaginally [16] [17] [18] [19] or rectally. 20 In 1 clinical trial, TFV gel applied vaginally resulted in quantifiable rectal fluid (RF) concentrations, with higher concentrations than those seen after oral dosing. 21 Although these initial findings suggest that vaginal dosing might provide some rectal mucosa protection in the setting of anal intercourse, more directly supporting data, including cross-compartment TFV diphosphate (TFV-DP) tissue concentrations, are needed. Consequently, a phase 1, cross-over, randomized trial in women was conducted to describe the steady-state, cross-compartmental pharmacokinetics (PK) and pharmacodynamics (PD) of the investigational study product, TFV reduced-glycerin (RG) 1% gel, applied vaginally or rectally. The trial also assessed the safety of vaginally applied TFV RG 1% gel. This formulation is better tolerated than the high glycerin (HG) formulation when applied rectally; 22 however, its safety when applied vaginally had not been evaluated.
METHODS

Study Design
MTN-014 was a phase 1, randomized, open-label, vaginal and rectal gel dosing cross-over study of TFV RG gel. Endpoints included drug concentrations in fluid and tissue from the vagina and rectum, safety of TFV RG gel, and acceptability of daily directly observed dosing (DOD). The study was conducted at the Bronx Prevention Center Clinical Research Site (Bronx, NY) under a protocol approved by the Columbia University Institutional Review Board, and in accordance with the Helsinki Declaration of 1975, as revised in 2000.
The investigational TFV RG gel study product was supplied by CONRAD (Arlington, VA) and manufactured by DPT Laboratories (San Antonio, TX). The gel pH was 4.0-5.5; the osmolality was approximately 836 mmol/kg and it was supplied in 4 mL prefilled, single-dose applicators.
Women were eligible if they were between 21 and 45 years of age (inclusive), HIV-uninfected, and willing, during the study period, to use effective contraception and abstain from using nonstudy vaginal or rectal products. Exclusion criteria included hepatitis B virus surface antigen seropositivity, active sexually transmitted infection, use of pre-or post-exposure HIV prophylaxis, pregnancy or breastfeeding, and significant gynecological, blood chemistry, or hematologic abnormalities. At screening, vaginal fluid (VF) and RF were collected for nucleic acid amplification testing for Neisseria gonorrhoeae and Chlamydia trachomatis, and VF was collected for a rapid trichomonas test. Blood was collected for safety laboratory evaluations (complete blood count, creatinine, alanine aminotransferase, and aspartate aminotransferase) and syphilis serology. Urine was collected for pregnancy testing.
Participants were randomized 1:1 to 1 of 2 sequences of gel administration periods (vaginal-rectal or rectal-vaginal) (Fig. 1) . Each period was 14 days long, separated by a 6-week washout period that enabled sample collection at a similar point in the participants' menstrual cycles. Participants presented daily for a DOD visit during each product-use period, including weekends, so that study staff could directly observe study product insertion. Each participant received 2 applicators per 14-day product-use period for use at home in case a DOD visit was not possible.
At the end of each product-use period, approximately 24 hours (h) after the final (14th) dose, blood, VF, RF, vaginal and rectal tissue biopsies, and endocervical cells (ECC) were collected. At the beginning of the second product-use period, VF and RF were collected. Safety was assessed at each follow-up visit by physical, pelvic, and rectal examinations. Participant attitudes about DOD and daily clinic visits were assessed through a face-to-face interview at enrollment and at the end of each product-use period.
Specimen Collection Methods
Blood was collected for plasma and peripheral blood mononuclear cell (PBMC) isolation. VF was collected by Dacron swab (posterior fornix), and cervicovaginal lavage (CVL) was collected after administering 10 mL of normal saline. ECC were collected by QIAGEN Digene cytobrush (Gaithersburg, MD) and, after elution from the cytobrush, total cell count (including squamous cells) and percent of viable cells were determined using trypan blue and a hemacytometer. RF was collected with a Merocel (Mystic, CT) sponge inserted anoscopically. Two 2-4 mm vaginal biopsies were collected (Tischler Rotating Biopsy Punch, Gynex Corporation, #1200 or 1008), 1 from each lateral vaginal wall. Four rectal biopsies were collected 15 cm from the anal verge through a sigmoidoscope (Wilson-Cook Max forceps; #G54167, cup diameter 3.3 mm, Cook Endoscopy, Winston-Salem, NC).
Laboratory Methods
TFV and TFV-DP concentrations were determined by previously described liquid chromatographic-tandem mass spectrometric methods validated 23 for each biological specimen source and relevant fluid collection device. 24, 25 TFV and TFV-DP concentrations were determined from a single biopsy from each source, vaginal or rectal, to minimize interbiopsy variation. For TFV, lower limits of quantification (LLOQ) for each matrix were: plasma, 0.31 ng/mL; CVL, 5 ng/mL; VF, 0.625 ng/swab; RF, 1.25 ng/sponge; and tissue, 0.05 ng/sample. TFV-DP was quantified in PBMC, ECC, and tissue homogenates using a previously described indirect assay which measured TFV after isolation of TFV-DP and enzymatic dephosphorylation to TFV. 25 The LLOQ of TFV-DP for all matrices was 50 fmol/sample. TFV-DP results were normalized to number of cells analyzed for PBMC and ECC and reported as fmol/million cells. Based on the number of cells analyzed, the median TFV-DP LLOQs for PBMC and ECC were 24 and 12 fmol/million cells, respectively. Tissue TFV and TFV-DP values were normalized to biopsy weight and reported as ng/mg and fmol/mg, respectively. Tissuespecific LLOQs were calculated by dividing the LLOQ by the weight of each analyzed tissue sample homogenate, and then calculating the median value. CVL concentrations were not adjusted for dilutional volume.
CVL and RF were tested for anti-HIV activity using the TZM-bl assay. 22, 26 Cellular debris was removed from the CVL by centrifugation, and the supernatant was aliquoted and stored at #270°C until tested. Sponge eluates were obtained by placing the sponge in the upper portion of a SpinX column (Corning Inc., Corning, NY). After centrifugation, eluates were aliquoted and stored at #270°C until tested. Two dilutions of each CVL and rectal sponge eluate were tested in triplicate along with HIV-1 BaL . Modest dilutions of mucosal fluids (1:4 for CVL and 1:37.5 for RF) were made to optimize the predose innate activity against the presumptive postdose drug-associated activity. Saline was used as a control for the mucosal fluid. Anti-HIV activity was measured by luminescent assay (BrightGlo; Promega Corp., Madison, WI). Inhibition was determined based on deviations from the HIV-1-only controls and presented as the percent inhibition.
Statistical Analysis
Descriptive statistics were used to summarize study population demographics, PK, and PD outcomes. Concentrations of TFV and TFV-DP in the dosing compartment (eg, vaginal concentration after vaginal dosing) were summarized and compared with concentrations in the cross-compartment (eg, vaginal concentration after rectal dosing). A linear mixed model was used to test for interaction between the product and use period. For PD data, percentage of change from predose values to postdose values was computed for CVL and RF, and compared between dosing compartment and crosscompartment delivery. In all randomized participants, number and percentage of adverse events (AEs) were tabulated by severity, category, and relationship to study product.
RESULTS
Study Population and Visit Performance
Fourteen women, recruited primarily from family planning and gynecology clinics in Bronx, New York, enrolled in the study between May and November 2014. The participants' mean age was 33.7 years; most were unmarried (79%), college-educated (57%), identified their race as Black or African American (50%) and their ethnicity as Hispanic (50%), and earned their own income (71%). Participants completed all study procedures except for 1 participant who opted not to undergo biopsies at the end of her second (vaginal) product-use period. As a result, there were 13, rather than 14, tissue samples collected after the 14-day vaginal product-use periods.
Study staff directly observed 358 of 392 expected doses (91%), including 100% of the final doses. A total of 32 doses were reported as used at home and 2 doses were reported as missed. The 32 nonobserved doses occurred at a variety of times across the 2 product-use periods, without evidence of clustering at the beginning or end (data not shown).
Pharmacokinetics
Plasma TFV concentrations were quantifiable in 10/14 samples (71%) 24 hours after the end of vaginal and rectal product-use periods, and median TFV plasma concentrations were similar, 0.58 ng/mL and 0.82 ng/mL, respectively ( Table 1) . Only 1 PBMC sample, collected after rectal dosing, had quantifiable TFV-DP. Although no participants had quantifiable TFV in plasma or RF samples at the end of the washout phase, VF samples from 2 participants starting rectal product-use periods had quantifiable TFV (327.5 and 0.938 ng/swab).
Median tissue-specific LLOQs of TFV and TFV-DP were each about 6 times smaller in vaginal tissue as compared to rectal tissue (Table 1) , reflecting the larger median weights of the vaginal versus rectal tissue samples (10.85 mg versus 1.85 mg, data not shown).
After vaginal dosing, TFV was detected in all (14/14) VF and nearly all (13/14) CVL samples, with median concentrations of 7138 ng/swab and 4485 ng/mL, respectively (Table 1) . These cannot be directly compared because the swab was not corrected for sample weight and the CVL was not corrected for dilutional effects of the lavage. TFV and TFV-DP were detected in nearly all, 12/13 (92%), vaginal tissue samples, with median concentrations of 8.5 ng/mg and 166 fmol/mg, respectively, and TFV-DP was detected in more than half, 8/14 (57%), of ECC, with a median concentration of 126.3 fmol/10 6 ECC.
Detection of vaginally applied TFV in the rectal compartment varied according to sample type. Although TFV was quantifiable in most (10/14) RF samples with a median concentration of 4.4 ng/sponge, TFV and TFV-DP were detected in only 1/13 (0.2 ng/mg) and 2/13 (59.8 and 76.5 fmol/mg) rectal tissue samples, respectively. The TFV rectal:vaginal concentration ratio in the 1 sample that had quantifiable rectal tissue TFV was 0.2:8.5 ng/mg or 1:42; the TFV-DP rectal:vaginal concentration ratios in the 2 samples that had quantifiable rectal tissue TFV-DP were 59.8:166 fmol/mg and 76.5:166 fmol/mg or approximately 1:3 and 1:2, respectively. As these rectal:vaginal ratios were calculable for only 3/26 samples, these estimates should be viewed with caution and may not represent the unmeasurable ratios in other participants.
After rectal dosing, similar to vaginal dosing, TFV was detected in most of dosing compartment samples (Table 1) . TFV was detected in 12/14 RF samples, with a median concentration of 202 ng/sponge, and in 12/14 rectal tissues, †The overall LLOQ of TFV was 0.05 ng/mg tissue and the overall LLOQ of TFV-DP was 50 fmol/mg of tissue. The tissue-specific LLOQ of TFV and of TFV-DP were calculated by dividing the overall LLOQ by the median weight of the biopsy samples from each anatomical location. As the median tissue weights obtained after each dosing route were similar, the LLOQs for vaginal and rectal tissue are based on the average of the tissue weights obtained after each dosing route.
‡Mean duration of time between the final dose at the end of each product-use period and vaginal tissue collection was 21.6 hours (SD 2.6 hours). §Mean duration of time between the final dose at the end of each product-use period and rectal tissue collection was 20.4 hours (SD 2.7 hours).
with a median concentration of 3.0 ng/mg. TFV-DP was detected in 10/14 (71%) rectal tissues, with a median concentration of 196 fmol/mg. As with vaginal dosing, detection of rectally applied TFV in the cervicovaginal compartment varied according to sample type. Although TFV was detected in most (9/14) VF samples, with a median concentration of 1.1 ng/swab, TFV was detected in only 3/14 CVL samples. In vaginal tissue homogenates, drug was detected in fewer than half, TFV in 6/ 14 and TFV-DP in 3/14 samples, with concentration medians largely below the limit of quantitation (BLQ); and in none of the ECC samples. Median LLOQs for TFV and TFV-DP in vaginal tissue samples were 0.0046 ng/mg and 4.61 fmol/mg, respectively; and despite a median cytobrush count of 5.0 · 10 6 cells, the median TFV-DP in ECC samples was BLQ. The vaginal:rectal tissue ratios for TFV after rectal dosing for the 6 samples that had quantifiable TFV in vaginal tissue were at least 0.0046 (the LLOQ):3.0 ng/mg or 1:652; and the vaginal: rectal tissue ratio for TFV-DP for the 3 samples that had quantifiable vaginal TFV-DP was at least 17.3:196 fmol/mg or 1:11. As above, these vaginal:rectal ratios should be viewed with caution because the ratios were calculable for only 9/28 samples.
Except for rectal sponge concentrations (P = 0.043), there were no statistically significant interactions between route of dosing and period of use in this trial. As above, because of the limited number of vaginal tissue samples with quantifiable concentrations, paired analyses of each participant's findings were not performed.
HIV Inhibition
Baseline CVL samples demonstrated modest anti-HIV activity (41% 6 14%) ( Table 2) , reflecting natural innate antiviral activity. After 14 days of vaginal product use, the anti-HIV activity increased to 71% (SD 29%) but was not significantly different (Table 2) . No significant change in the inhibition of HIV was observed with RF collected after vaginal dosing or in CVL or RF after rectal dosing.
Safety
One participant experienced weight loss during the rectal phase. Initially categorized as a grade 2 AE, it progressed to a grade 3 event, resulting in a product hold of 2 days; it was due to social stress and not related to product use. Two other grade 2 AEs were observed during the rectal phase, bacterial vaginosis (grade 2) and vaginal trichomoniasis (grade 2), each in different participants, and neither event was deemed related to product use.
Acceptability of DOD
Most participants (23/28) reported always inserting study product herself, rather than having study staff insert it, and most reported feeling "comfortable" (12/28) or "very comfortable" (7/28) with clinicians observing them. Most reported that they liked (7/28) or were neutral (16/28) about the required daily study site visits.
DISCUSSION
Women may be exposed to HIV through both vaginal and rectal intercourse, yet few studies have assessed the bidirectional PK of antiretroviral 15, 21 or other pharmacologic agents between vaginal and rectal compartments. Understanding cross-compartment PK and PD of vaginally and rectally applied HIV prevention products is crucial to determine their potential to provide HIV protection, regardless of the compartment to which product is applied or route of sexual exposure. 6 In this open-label, cross-over, randomized phase 1 trial, we found that when used for 14 days either vaginally or rectally, TFV RG gel was safe and acceptable in adult women. DOD was acceptable in the context of this clinical trial.
We applied a comprehensive anatomical sampling strategy to understand the distribution and time course of TFV and TFV-DP in cervicovaginal and RFs and tissue and to enable multicompartment modeling in secondary analyses. Approximately 24 hours after the end of each 14-day dosing period, cross-compartment detection of TFV was more evident in fluid samples than tissue samples, due largely to increased LLOQ in tissue samples, especially for TFV-DP. In addition, cross-compartment tissue TFV (but not TFV-DP) was detected more frequently after rectal dosing than after vaginal dosing, based on the proportion of cross-compartment tissue samples with quantifiable concentrations. On the other hand, ratios of cross-compartment tissue concentrations for both TFV and TFV-DP were larger after vaginal dosing compared with rectal dosing. This is the first study to assess vaginal use of the RG formulation of TFV gel. The RG and HG formulations of TFV gel have very similar physical and chemical properties except for glycerin content (5% versus 20%) and osmolality (836 versus 3111 mmol/kg). 22 Previous clinical studies evaluating vaginal use of TFV gel used the HG formulation; 8, 27, 28 however, the RG formulation offers important advantages over the HG formulation because epithelial integrity is better preserved while drug release and anti-HIV-1 activity are comparable. 22 A comparison of findings after vaginal dosing of TFV RG gel in this study with findings after vaginal dosing of TFV HG gel in MTN-001, which had similar anatomical and temporal sampling, indicates largely overlapping concentration distributions for serum/plasma (Table 3) . Vaginal tissue TFV, vaginal tissue TFV-DP, and CVL TFV concentrations after vaginal dosing seemed higher after TFV HG gel in MTN-001 when compared with TFV RG gel in MTN-014. This might be accounted for by the earlier sampling time after TFV HG gel versus TFV RG gel dosing (;13 versus ;24 hours), but this should only affect CVL and tissue TFV modestly and not affect TFV-DP because of the much longer TFV-DP half-life. 29 When comparing daily rectal TFV RG gel dosing between MTN-014 and the 1-week dosing arm of CHARM-01, 30 which both used similarly timed postdose sampling, a mixed picture emerges: serum/plasma, RF TFV, and CVL TFV concentrations were higher in CHARM-01; rectal tissue TFV concentrations were similar; and rectal tissue TFV-DP concentrations were lower in CHARM-01, with 25% of samples BLQ in both studies and a wider range of values in MTN-014 (Table 3) . For the vaginal compartment, too few samples had quantifiable drug after rectal dosing to make a meaningful comparison.
Oral dosing of TDF protects individuals at risk of HIV acquisition through either vaginal or rectal exposure to HIV, presumably because vaginal and rectal concentrations of TFV-DP are sufficient to prevent HIV infection, 1,2 although it must be noted that vaginal and rectal TFV-DP concentrations have not definitively been shown to be the relevant site and analyte for HIV protection. However, the estimated tissue TFV-DP concentrations among the primary PrEP randomized clinical trials, including vaginal dosing in the VOICE gel arm, offer a good explanation of trial outcomes and we would therefore rank tissue TFV-DP as the most influential determinant of PrEP outcomes, regardless of dosing route. 5 If one compares vaginal tissue concentrations of TFV and TFV-DP associated with daily rectal dosing of TFV RG gel in this study with the oral TDF dosing arm in MTN-001, an oral regimen proven protective of predominantly vaginal HIV exposure risk in several randomized control trials, most samples after both dosing routes are BLQ, rendering a comparison of "protective" concentrations impossible. A comparison of rectal tissue TFV and TFV-DP concentrations 24 hours after daily vaginal dosing in this study with concentrations achieved 24 hours after daily oral dosing in HPTN 066, a regimen protective for rectal HIV exposure risk, reveals the daily oral regimen results in higher concentrations. Vaginal dosing of TFV RG gel may therefore be less protective against rectal transmission of HIV than oral dosing of TDF. We believe the predose 24-hour TFV-DP tissue concentrations to be most relevant to a daily dosing scenario because this represents the time of lowest concentration.
We used the TZM-bl cell assay 22, 26, 31 to assess the relationship between TFV concentration and HIV viral replication in fluid samples taken from both vaginal and 50 ) of TFV in the TZM-bl assay is 611 ng/mL. Although some CVL samples collected after vaginal dosing had TFV concentrations above this, the modest dilution used for the lavage in the assay (1:4) likely resulted in loss of TFV-associated anti-HIV activity. Thus, although there was an increase in anti-HIV activity postvaginal dosing, overall it was not significant. The concentration of TFV in CVL after rectal dosing and in RF after either dosing regimen failed to achieve the in vitro EC 50 concentration; however, lack of activity in the TZM-bl assay does not necessarily mean that vaginal or rectal use of TFV RG gel would fail to provide cross-compartment protection from HIV acquisition 24 hours after application. Recent work by others indicates that lactobacillus-dominant vaginal flora may enhance 32, 33 and inflammatory cytokines may diminish 34, 35 the protective efficacy of vaginal TFV gel in healthy HIV-negative women. Such factors may be relevant to the findings in this study and additional analyses are underway to examine the relationship between vaginal flora, cytokines, and TFV concentrations. This study had several strengths: the DOD schedule maximized adherence, the cross-over design allowed each participant to serve as her own control, and sampling 24 hours after 14 days of daily dosing ensured samples were collected after steady-state concentrations had been established. This sampling time point, based on evidence of persistent TFV in vaginal aspirates and tissue for up to 24 h after the last of 14 daily doses in a TFV HG 1% gel study, 36 sheds light on the lowest (predose) concentrations in daily dosing regimens. Finally, rectal biopsy samples were collected at an anatomical location associated with the highest concentration of cell-free and cell-associated HIV surrogates in coital simulation studies. 29 The small number of tissue samples with quantifiable levels limited our ability to perform within-participant comparisons. In addition, the rectal tissue-specific LLOQs, 6 times higher than the vaginal tissue-specific LLOQs, limited our ability to detect TFV and TFV-DP in rectal tissue. This difference in LLOQs may explain, at least in part, the higher proportion of rectal tissue samples with unquantifiable concentrations after vaginal dosing as compared to the proportion of vaginal tissue samples after rectal dosing. Of note, we have reported VF TFV and RF TFV results in ng/swab and ng/sponge, respectively. Because these concentrations were not normalized to collected fluid weights, although general statements regarding relative amount of drug in each matrix can be made, a direct comparison between studies is challenging because of potential differences in absolute fluid volume acquired by each collection device. Finally, our inferences about cross-compartment gradients and levels of protection as assessed from published literature come from several different studies-a combination of randomized control trials and PK-focused studies-rather than studies that directly assess both concentration and protection in the same set of participants.
In conclusion, we found that TFV RG gel, applied rectally and vaginally for 14 days each, resulted in low crosscompartment fluid TFV concentrations. These concentrations were often below the quantitative limits of detection, making it difficult to compare the concentrations with the anatomically corresponding levels associated with daily oral dosing regimens known to be protective. Although it is highly likely that, once licensed, a vaginal microbicide will also be used rectally, our data suggest that application of TFV RG 1% gel directly to the vagina is required for protection from vaginal HIV exposures and, similarly, application directly to the rectum is required for rectal HIV protection.
